Welcome to our dedicated page for Tango Therapeutics SEC filings (Ticker: TNGX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Tango Therapeutics, Inc. (TNGX) SEC filings page provides access to the company’s official regulatory disclosures as a Nasdaq-listed clinical-stage biotechnology company. Tango Therapeutics files a range of documents with the U.S. Securities and Exchange Commission that describe its financial condition, capital markets activities, and key corporate events, complementing its focus on discovering and developing precision cancer medicines using synthetic lethality.
Through Forms 8-K, Tango Therapeutics reports material events such as equity financings, at-the-market offering programs, and private placements, including underwriting agreements for registered offerings of common stock and pre-funded warrants, and securities purchase agreements for PIPE transactions. These filings often explain the intended use of proceeds, which the company has stated includes advancing its pipeline and supporting working capital and general corporate purposes, as well as expectations for its cash runway.
Other 8-K filings furnish press releases that summarize quarterly financial results and provide business highlights, including updates on clinical trials for vopimetostat (TNG462), TNG456, and TNG260. Filings also document corporate governance developments, such as leadership transitions, board appointments, and executive departures. Registration statements and prospectus supplements referenced in these filings outline the structure and terms of Tango Therapeutics’ capital raising activities.
On Stock Titan, users can review Tango Therapeutics’ SEC filings alongside AI-powered summaries that help explain the significance of each document. This includes quick insights into quarterly earnings releases (often furnished on Form 8-K), material financing agreements, at-the-market sales agreements, and other key disclosures. The filings page supports investors who want to understand how Tango Therapeutics funds its clinical-stage oncology programs, manages its capital structure, and reports material corporate events under SEC requirements.